FILGRASTIM

Relapse

Andrew Yee, MDprotein_peptidePhase 2Active

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 73/ 100

Competitive context

8 Active assets in the Relapse cohort.

Asset / Sponsor	Phase	Rating
Cytosin-Arabinosid University of Miami	Phase 2	B
CIS-DIAMMINEDICHLOROPLATINUM II Andrew Yee, MD	Phase 2	CCC
Naltrexone Massachusetts General Hospital	Phase 2	CCC
Eloxatin University of Miami	Phase 2	CCC
Calcium folinate pentahydrate Fudan University	Phase 2	CCC

View all 13 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant

BBB

Indicative ·

79 / 100

Burkitt lymphomaDormant

BBB

Indicative ·

78 / 100

Hodgkins lymphomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.